<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aberrant DNA methylation is a key pathological mechanism in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), and provides rationale for the clinical development of hypomethylating agents (HMAs) for the treatment of these diseases </plain></SENT>
<SENT sid="1" pm="."><plain>One HMA, <z:chebi fb="0" ids="2038">azacitidine</z:chebi> (VidazaÂ®, Celgene Corp.), has demonstrated improved survival versus conventional care regimens in patients with intermediate-2/high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (20-30% blasts) and has a favorable tolerability profile </plain></SENT>
<SENT sid="2" pm="."><plain>Emerging evidence indicates that <z:chebi fb="0" ids="2038">azacitidine</z:chebi> can have an immunomodulatory effect by, for example, increasing functional regulatory T-cell (Treg) numbers and killer-cell-immunoglobulin-like receptor expression </plain></SENT>
<SENT sid="3" pm="."><plain>Allogeneic hematopoietic progenitor cell transplantation (allo HPCT) is the only potentially curative treatment approach in patients with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Unfortunately, allo HPCT in these settings is limited because most patients are ineligible due to age/comorbidities, or are at a high risk of treatment failure due to disease relapse </plain></SENT>
<SENT sid="5" pm="."><plain>Recent studies have shown that <z:chebi fb="0" ids="2038">azacitidine</z:chebi> after allo HPCT increases Treg numbers while inducing a cytotoxic CD8+ T-cell response, suggesting a potential mechanism for augmenting the graft-versus-<z:hpo ids='HP_0001909'>leukemia</z:hpo> (GvL) effect without increasing <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host-disease</z:e> (GVHD) </plain></SENT>
<SENT sid="6" pm="."><plain>In patients at a high risk of relapse following allo HPCT, pre-emptive <z:chebi fb="0" ids="2038">azacitidine</z:chebi> may help prevent/delay relapse </plain></SENT>
<SENT sid="7" pm="."><plain>For patients who have relapsed following allo HPCT, <z:chebi fb="0" ids="2038">azacitidine</z:chebi> may be a salvage therapy option, either as monotherapy or in combination with donor lymphocyte infusions (DLI) </plain></SENT>
<SENT sid="8" pm="."><plain>In this mini-review, we discuss these emerging clinical data for HMAs in the post-allo HPCT regimens and highlight the possible future role of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> in this setting </plain></SENT>
</text></document>